Mirdametinib (Gomekli) wins FDA approval, bringing relief to NF-1 patients with surgically inoperable plexiform neurofibromatosis worldwide

References

[1] Miller DT , Freedenberg D , Schorry E , et al. Health supervision for children with neurofibromatosis type 1. Pediatrics. 2019; 143 (5): e20190660.

[2] Buono FD , Grau LE , Sprong ME , Morford KL , Johnson KJ , Gutmann DH . Pain symptomology, functional impact, and treatment of people with neurofibromatosis type 1. J Pain Res. 2019; 12: 2555- 2561.

[3] Canadian Agency for Drugs and Technologies in Health . CADTH Reimbursement Recommendation. 2023.

[4] U.S. Food and Drug Administration . FDA Approves Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection. Accessed February 21 2025.

[5] Weiss BD , Wolters PL , Plotkin SR , et al. NF106:a neuro-fibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. J Clin Oncol. 2021; 39 (7): 797- 806.

[6] Moertel CL , Hirbe AC , Shuhaiber HH , et al. ReNeu:a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J Clin Oncol. 2025; 43 (6): 716- 729.

[7] Peacock BC , Tripathy S , Hanania HL , Wang HY , Sadighi Z , Patel AB . Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1. JNO. 2024; 167 (3): 515- 522.

[8] Verzijl CRC , van de Peppel IP , Eilers RE , et al. Pharmacological inhibition of MEK1/2 signaling disrupts bile acid metabolism through loss of Shp and enhanced Cyp7a1 expression. Biomed Pharmacother. 2023; 159: 114270.

[9] Hummel L , Ameri M , Alqahtani S , Sadighi Z , Al-Zubidi N . Incidence of ophthalmological complications in NF-1 patients treated with MEK inhibitors. Curr Oncol. 2024; 31 (5): 2644- 2649.

[10] Ioannou M , Lalwani K , Ayanlaja AA , Chinnasamy V , Pratilas CA , Schreck KC . MEK inhibition enhances the antitumor effect of radiotherapy in NF1-deficient glioblastoma. Mol Cancer Ther. 2024; 23 (9): 1261- 1272.

[11] Raut SB , Joly F , Haass NK , et al. The clinically relevant MEK inhibitor mirdametinib combined with D-cycloserine and prediction error disrupts fear memory in PTSD models. Transl Psychiatry. 2024; 14 (1): 492.

[12] Suman I , Šimić L , Čanadi Jurešić G , Buljević S , Klepac D , Domitrović R . The interplay of mitophagy, autophagy, and apoptosis in cisplatin-induced kidney injury:involvement of ERK signaling pathway. Cell Death Discov. 2024; 10 (1): 98.

RIGHTS & PERMISSIONS

The Author(s). Malignancy Spectrum published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.